Screener
Enliven Therapeutics ELVN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Stockholders' equity: | ||
| Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none | — | — |
| Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 60,889,655 and 59,440,045 atMarch 31, 2026 and December 31, 2025, respectively | 61 | 59 |
| Additional paid-in capital | 824,479 | 806,373 |
| Accumulated other comprehensive (loss) income | (382) | 334 |
| Accumulated deficit | (370,793) | (347,166) |
| Total stockholders’ equity | 453,365 | 459,600 |
| Total liabilities and stockholders' equity | $464,852 | $476,168 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's total equity?
- Enliven Therapeutics (ELVN) reported total equity of $453.37M in Q1 2026.
- How has Enliven Therapeutics's total equity changed year-over-year?
- Enliven Therapeutics's total equity increased by 57.3% year-over-year, from $288.3M to $453.37M.
- What is the long-term trend for Enliven Therapeutics's total equity?
- Over 5 years (2020 to 2025), Enliven Therapeutics's total equity has grown at a 40.3% compound annual growth rate (CAGR), from $84.44M to $459.6M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Enliven Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude